Vilken av studierna på sidan var det som du inte klarade av att läsa?
1. Afsar et al., SSRN., Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting,
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3734478.
2.
Ahmed et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.191, A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness,
https://www.sciencedirect.com/science/article/pii/S1201971220325066.
3.
Alam et al., European Journal ofMedical and Health Sciences, doi:10.24018/ejmed.2020.2.6.599, Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Study,
https://ejmed.org/index.php/ejmed/article/view/599.
7.
Behera et al., medRxiv, doi:10.1101/2020.10.29.20222661v1, Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study,
https://www.medrxiv.org/content/10.1101/2020.10.29.20222661v1.
8.
Bernigaud et al., Annals of Dermatology and Venereology, doi:10.1016/j.annder.2020.09.231, Ivermectin benefit: from scabies to COVID-19, an example of serendipity,
https://www.sciencedirect.com/science/article/pii/S015196382030627X.
9.
Budhiraja et al., medRxiv, doi:10.1101/2020.11.16.20232223, Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the Correlates of their Mortality: An Indian Experience,
https://www.medrxiv.org/content/10.1101/2020.11.16.20232223v1.
10.
Cadegiani et al., medRxiv, doi:10.1101/2020.10.31.20223883, Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients,
https://www.medrxiv.org/content/10.1101/2020.10.31.20223883v1.
11.
Camprubí et al., PLoS ONE, 15:11, doi:10.1371/journal.pone.0242184, Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients,
https://journals.plos.org/plosone/..le?id=10.1371/journal.pone.0242184.
12.
Carvallo et al., medRxiv, doi:10.1101/2020.09.10.20191619, Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19,
https://www.medrxiv.org/content/10.1101/2020.09.10.20191619v1.
13.
Carvallo (B) et al., Journal of Biomedical Research and Clinical Investigation, doi:10.31546/2633-8653.1007, Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel,
https://medicalpressopenaccess.com/upload/1605709669_1007.pdf.
14.
Carvallo (C) et al., NCT04425850, Usefulness of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19 (IVERCAR),
https://clinicaltrials.gov/ct2/show/results/NCT04425850.
15.
Chaccour et al., Research Square, doi:10.21203/rs.3.rs-116547/v1, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial,
https://www.researchsquare.com/article/rs-116547/v1.
16.
Chachar et al., International Journal of Sciences, 9:31-35, doi:10.18483/ijSci.2378, Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients,
https://www.ijsciences.com/pub/article/2378.
17.
Concato et al., NEJM, 342:1887-1892, doi:10.1056/NEJM200006223422507,
https://www.nejm.org/doi/full/10.1056/nejm200006223422507.
20.
Elgazzar et al., Research Square, doi:10.21203/rs.3.rs-100956/v2, Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic,
https://www.researchsquare.com/article/rs-100956/v3.
21.
Elgazzar (B) et al., Research Square, doi:10.21203/rs.3.rs-100956/v2, Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic,
https://www.researchsquare.com/article/rs-100956/v3.
22.
Espitia-Hernandez et al., Biomedical Research, 31:5, Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study,
https://www.biomedres.info/biomedi..-proof-of-concept-study-14435.html.
23.
Gorial et al., medRxiv, doi:10.1101/2020.07.07.20145979, Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial),
https://www.medrxiv.org/content/10.1101/2020.07.07.20145979v1.
24.
Hashim et al., medRxiv, doi:10.1101/2020.10.26.20219345, Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq,
https://www.medrxiv.org/content/10.1101/2020.10.26.20219345v1.
25.
Hellwig et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106248, A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin,
https://www.sciencedirect.com/science/article/pii/S0924857920304684.
26.
Khan et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.08.007, Ivermectin treatment may improve the prognosis of patients with COVID-19,
https://www.archbronconeumol.org/e..ognosis-articulo-S030028962030288X.
27.
Krolewiecki et al., SSRN, Antiviral Effect of High-Dose Ivermectin in Adults with COVID-19: A Pilot Randomised, Controlled, Open Label, Multicentre Trial,
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3714649.
28.
Lee et al., Arch Intern Med., 2011, 171:1, 18-22, doi:10.1001/archinternmed.2010.482, Analysis of Overall Level of Evidence Behind Infectious Diseases Society of America Practice Guidelines,
https://jamanetwork.com/journals/j..nternalmedicine/fullarticle/226373.
29.
Mahmud et al., Clinical Trial Results, NCT04523831, Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,
https://clinicaltrials.gov/ct2/show/results/NCT04523831?view=results.
30.
McLean et al., Open Forum Infect. Dis. September 2015, 2:3, doi:10.1093/ofid/ofv100, Impact of Late Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a Randomized Trial,
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4525010/.
31.
Niaee et al., Research Square, doi:10.21203/rs.3.rs-109670/v1, Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial,
https://www.researchsquare.com/article/rs-109670/v1.
33.
Podder et al., IMC J. Med. Science, 14:2, July 2020, Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study,
http://imcjms.com/registration/journal_abstract/353.
34.
Rajter et al., Chest, doi:10.1016/j.chest.2020.10.009, Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study),
https://www.sciencedirect.com/science/article/pii/S0012369220348984.
35.
Shouman et al., NCT04422561, Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contacts with Patients of COVID-19,
https://clinicaltrials.gov/Provide..cs/61/NCT04422561/Prot_SAP_000.pdf.
36.
Soto-Becerra et al., medRxiv, doi:10.1101/2020.10.06.20208066, Real-World Effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: Results of a target trial emulation using observational data from a nationwide Healthcare System in Peru,
https://www.medrxiv.org/content/10.1101/2020.10.06.20208066v1.
37.
Spoorthi et al., IAIM, 2020, 7:10, 177-182, Utility of Ivermectin and Doxycycline combination for the treatment of SARSCoV-2,
http://iaimjournal.com/wp-content/..oads/2020/10/iaim_2020_0710_23.pdf.
38.
Sweeting et al., Statistics in Medicine, doi:10.1002/sim.1761, What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data,
https://onlinelibrary.wiley.com/doi/10.1002/sim.1761.
39.
Treanor et al., JAMA, 2000, 283:8, 1016-1024, doi:10.1001/jama.283.8.1016, Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial,
https://jamanetwork.com/journals/jama/fullarticle/192425.
40.
Vallejos et al., Coronavirus in Argentina: Warnings and evidence on the consumption of ivermectin against Covid-19,
https://totalnewsagency.com/2020/1..de-ivermectina-contra-el-covid-19/.
41.
Zhang et al., JAMA, 80:19, 1690, doi:10.1001/jama.280.19.1690, What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes,
https://jamanetwork.com/journals/jama/fullarticle/188182.
